Latest News and Press Releases

Want to stay updated on the latest news?

Sign into Reader Account Create Reader Account

March 16, 2017 16:05 ET | Source: Curis, Inc

Curis to Present at the Oppenheimer & Co. Inc. 27th Annual Healthcare Conference

LEXINGTON, Mass., March 16, 2017 (GLOBE NEWSWIRE) -- March 16, 2017 - Curis, Inc. (NASDAQ:CRIS), a biotechnology company focused on the development and commercialization of innovative drug...
March 09, 2017 07:00 ET | Source: Curis, Inc

Curis Reports Fourth Quarter and Year-End 2016 Financial Results

-- Company Announces $45 million Debt Transaction with HealthCare Royalty Partners Secured with Future Erivedge® Royalty -- -- Management to host conference call today at 8:30 a.m. EST -- LEXINGTON,...
March 07, 2017 07:05 ET | Source: Curis, Inc

Curis to Release Fourth Quarter and Year End 2016 Financial Results and Hold Conference Call on March 9, 2017

LEXINGTON, Mass., March 07, 2017 (GLOBE NEWSWIRE) -- Curis, Inc. (Nasdaq:CRIS), a biotechnology company focused on the development and commercialization of innovative and effective drug candidates...
March 01, 2017 18:33 ET | Source: Curis, Inc

Curis to Present at the Cowen and Company 37th Annual Health Care Conference

LEXINGTON, Mass., March 01, 2017 (GLOBE NEWSWIRE) -- Curis, Inc. (NASDAQ:CRIS), a biotechnology company focused on the development and commercialization of innovative drug candidates for the...
February 17, 2017 16:30 ET | Source: Curis, Inc

Curis to Present at the 2017 RBC Capital Markets Global Healthcare Conference

LEXINGTON, Mass., Feb. 17, 2017 (GLOBE NEWSWIRE) -- Curis, Inc. (NASDAQ:CRIS), a biotechnology company focused on the development and commercialization of innovative drug candidates for the...
January 09, 2017 07:00 ET | Source: Curis, Inc

Curis and Aurigene Extend Exclusivity Period of Immuno-Oncology and Precision Oncology Collaboration

LEXINGTON, Mass., Jan. 09, 2017 (GLOBE NEWSWIRE) -- Curis, Inc. (Nasdaq:CRIS), a biotechnology company focused on the development and commercialization of innovative and effective drug candidates...
January 06, 2017 16:12 ET | Source: Curis, Inc

Curis Reports Inducement Grants Under NASDAQ Listing Rule 5635(c)(4)

LEXINGTON, Mass., Jan. 06, 2017 (GLOBE NEWSWIRE) -- Curis, Inc. (NASDAQ:CRIS), a biotechnology company focused on the development and commercialization of innovative and effective drug candidates...
November 28, 2016 07:00 ET | Source: Curis, Inc

Curis Announces Full Approval of Roche’s Erivedge® in the European Union

LEXINGTON, Mass., Nov. 28, 2016 (GLOBE NEWSWIRE) -- Curis, Inc. (Nasdaq:CRIS), a biotechnology company focused on the development and commercialization of innovative and effective drug candidates...
November 14, 2016 07:00 ET | Source: Curis, Inc

Curis Announces Appointment of Lori A. Kunkel, M.D. to Board of Directors

LEXINGTON, Mass., Nov. 14, 2016 (GLOBE NEWSWIRE) -- Curis, Inc. (NASDAQ:CRIS), a biotechnology company focused on the development and commercialization of innovative and effective drug...
November 09, 2016 12:15 ET | Source: Curis, Inc

Curis Presents Early Clinical Pharmacokinetic and Biomarker Data from CA-170’s Phase 1 Trial at the SITC 2016 Conference

LEXINGTON, Mass., Nov. 09, 2016 (GLOBE NEWSWIRE) -- Curis, Inc. (Nasdaq:CRIS), a biotechnology company focused on the development and commercialization of innovative and effective drug candidates...